- WORLD EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Organigram Forms Partnership With Front-Line Harm Reduction Groups
Organigram Holdings entered a partnership to provide front-line harm reduction workers in New Brunswick with a life-saving tool capable of reversing negative effects of opioids, including fentanyl overdose.
Organigram Holdings (TSXV:OGI; OTCQB:OGRMF) entered a partnership to provide front-line harm reduction workers in New Brunswick with a life-saving tool capable of reversing negative effects of opioids, including fentanyl overdose.
As quoted in the press release:
The partnership comes in response to an expressed need by community groups working under the Alliance of New Brunswick AIDS organizations. These groups work on the front lines of opioid addiction, providing needle exchange and additional services to opioid users in the province’s urban centres. Previously, these groups were unable to supply Naloxone kits (which range between $50 – $100 each) to their staff.
“Fentanyl use, misuse and overdose are an issue of major concern in Canada. We have watched the devastation in other parts of the country, and as part of our contribution to the health and welfare of New Brunswickers, we want to do what we can to help ensure our front-line teams are (better) equipped to handle the crisis,” says Organigram Chief Executive Officer Greg Engel.
Click here to read the full press release.
Source: www.marketwired.com
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.